Introduction: BioPharma SHAKTI’s Role in Biologics Innovation

BioPharma SHAKTI is an initiative launched by the Department of Biotechnology (DBT) in 2023 to boost India’s biologics sector by promoting advanced technologies, including non-animal models for drug development. India’s biologics market, valued at approximately USD 11 billion in 2023 with a compound annual growth rate (CAGR) of 20% (IBEF 2023), stands to benefit substantially from this push. The initiative allocates INR 150 crore under the DBT budget 2023-24 to support research and adoption of alternative testing methods, aiming to reduce reliance on animal models by 40% within five years (DBT 2023). This is significant for ethical compliance, cost reduction, and faster drug development in a sector critical for India’s pharmaceutical innovation ecosystem.

Regulatory and Legal Framework Governing Biologics and Animal Testing

The manufacture and clinical testing of biologics in India are regulated primarily under the Drugs and Cosmetics Act, 1940 (Sections 3, 5, and 27) which define standards and approval procedures. The ethical use of animals in research falls under the Prevention of Cruelty to Animals Act, 1960, which mandates humane treatment and restricts unnecessary animal testing. The New Drugs and Clinical Trials Rules, 2019 (Rule 122DAB) explicitly encourage the use of alternative, non-animal testing methods where validated. Additionally, Article 21 of the Constitution (Right to Life) underpins ethical considerations in biomedical research, reinforcing the need for humane and scientifically sound practices.

• Drugs and Cosmetics Act ensures quality and safety of biologics.
• Prevention of Cruelty to Animals Act governs ethical animal testing.
• Rule 122DAB incentivizes adoption of validated alternative testing methods.
• Article 21 supports ethical standards in research.

Economic Impact of Non-Animal Models in India’s Biologics Sector

India’s biologics market is expanding rapidly, with exports growing 18% in FY 2022-23 (Ministry of Commerce, 2023). However, animal testing constitutes about 70% of preclinical trials (ICMR 2022), inflating costs and timelines. Adoption of non-animal models such as organ-on-chip and 3D cell cultures, which demonstrate 85% predictive accuracy compared to 60-70% for animal models (Nature Biotechnology, 2023), can reduce R&D costs by up to 30% and shorten drug development by 1-2 years (NITI Aayog 2022). This efficiency gain is critical for India to compete globally, especially as the worldwide biologics market is projected to reach USD 580 billion by 2030 (Grand View Research 2023).

• Non-animal models improve predictive accuracy and reduce failures in clinical phases.
• Cost savings can be redirected towards innovation and scaling production.
• Faster timelines enhance export competitiveness.
• BioPharma SHAKTI’s INR 150 crore funding targets these efficiencies.

Key Institutions Driving Non-Animal Model Adoption

The Department of Biotechnology (DBT) leads policy formulation and funding for biotech innovation, including BioPharma SHAKTI. The Indian Council of Medical Research (ICMR) provides ethical guidelines and oversight for biomedical research, ensuring compliance with animal welfare laws. The Central Drugs Standard Control Organization (CDSCO) regulates approval of biologics and clinical trials, including validation of alternative testing methods. The Council of Scientific and Industrial Research (CSIR) develops new technologies for non-animal testing, while the Biotechnology Industry Research Assistance Council (BIRAC) facilitates startups and industry-academia collaborations to scale innovations.

• DBT: Policy and funding
• ICMR: Ethical oversight
• CDSCO: Regulatory approvals
• CSIR: Technology development
• BIRAC: Industry facilitation

Comparative Analysis: India vs European Union on Non-Animal Testing Regulations

Critical Gaps in India’s Regulatory and Innovation Ecosystem

India lacks a comprehensive regulatory framework mandating the phased reduction of animal testing in biologics, resulting in inconsistent adoption of non-animal models across the industry. This regulatory gap slows the pace of transformation compared to global peers like the EU. Additionally, limited infrastructure and validation centres for alternative testing methods constrain scalability. The absence of harmonized guidelines between CDSCO and ICMR creates ambiguity in protocol approvals, delaying clinical translation.

• No unified mandate for animal testing phase-out.
• Insufficient validation infrastructure for alternative models.
• Regulatory overlaps between CDSCO and ICMR.
• Limited industry awareness and capacity-building initiatives.

Significance and Way Forward

BioPharma SHAKTI’s focus on non-animal models can elevate India’s biologics sector by aligning ethical standards with global norms, reducing R&D costs, and accelerating drug development. To realize this potential, India must:

• Establish a unified regulatory framework mandating phased animal testing reduction.
• Expand validation centres for alternative testing technologies.
• Enhance coordination between CDSCO and ICMR for streamlined approvals.
• Promote industry-academia partnerships through BIRAC to scale innovations.
• Invest in capacity building and awareness programs on non-animal models.

Such measures will improve India’s export competitiveness, ethical compliance, and innovation capacity in biologics manufacturing.